Protalix Biotherapeutics
2:30 PM - 2:45 PM (EST), Tuesday, February 7, 2023 ・ Winter Garden
Protalix is a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by our proprietary ProCellEx® plant cell-based protein expression system. Our pipeline consists of proprietary, potentially clinically superior versions of recombinant therapeutic proteins that target established pharmaceutical markets.
Protalix is proud to be the first company to gain FDA approval for a plant cell culture expressed protein. Protalix’s ProCellEx® platform has the ability to manufacture complex proteins, antibodies, and vaccines and has the ability to orally deliver certain therapeutic proteins as demonstrated in animal models.
Protalix is proud to be the first company to gain FDA approval for a plant cell culture expressed protein. Protalix’s ProCellEx® platform has the ability to manufacture complex proteins, antibodies, and vaccines and has the ability to orally deliver certain therapeutic proteins as demonstrated in animal models.
Ticker:
PLX
Exchange:
NYSE American
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Israel
Year Founded:
Not Provided
Main Therapeutic Focus:
Orphan/Rare Diseases
Lead Product in Development:
PRX-102, PRX-115, PRX-119
Development Phase of Primary Product:
NDA Preparation / In Review
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
